• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S ADR (NY: NVO )

    136.97 +0.09 (+0.07%)
    Official Closing Price Updated: 7:00 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,112,197
    Open 136.57
    Bid (Size) 135.28 (1)
    Ask (Size) 136.97 (3)
    Prev. Close 136.88
    Today's Range 135.92 - 137.15
    52wk Range 86.96 - 148.15
    Shares Outstanding N/A
    Dividend Yield 1.29%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    2 No-Brainer Healthcare Stocks to Buy With $1,000
    There are no certainties in equity markets, but these stocks look highly likely to deliver outsized returns. 
    Via The Motley Fool
    Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
    Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,... 
    Via Benzinga

    Performance

    YTD
    +34.14%
    +34.14%
    1 Month
    +4.08%
    +4.08%
    3 Month
    +0.68%
    +0.68%
    6 Month
    +10.95%
    +10.95%
    1 Year
    +47.80%
    +47.80%

    More News

    Read More
    RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
    Via News Direct
    These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
    Via The Motley Fool
    Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
    Via The Motley Fool
    What the Options Market Tells Us About Novo Nordisk
    Via Benzinga
    If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,900 Today
    Via Benzinga
    A Glimpse Into The Expert Outlook On Novo Nordisk Through 8 Analysts
    Via Benzinga
    Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages
    Via Benzinga
    Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
    Via Benzinga
    Topics Economy
    Exposures Supply Chain
    Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
    Via The Motley Fool
    Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
    Via Benzinga
    Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
    Via Benzinga
    Unpacking the Latest Options Trading Trends in Novo Nordisk
    Via Benzinga
    Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages
    Via Benzinga
    Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
    Via The Motley Fool
    Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
    Via The Motley Fool
    Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
    Via The Motley Fool
    These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
    Via The Motley Fool
    Is Madrigal Pharmaceuticals Stock a Buy?
    Via The Motley Fool
    3 Fantastic Growth Stocks to Buy in August
    Via The Motley Fool
    Could Viking Therapeutics Become the Next Novo Nordisk?
    Via The Motley Fool
    Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
    Via Benzinga
    Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
    Via Benzinga
    Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.